Clinical trial
NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly…
NCT00499122 · University of Miami, Other · Completed
Key facts
| NCT number | NCT00499122 |
|---|---|
| Title | NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer |
| Official title | Phase II Study of Neoadjuvant Treatment With NOV-002 in Combination With Doxorubicin and Cyclophosphamide Followed by Docetaxel in Patients With Stages IIB-IIIC Breast Cancer |
| Lead sponsor | University of Miami, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Cyclophosphamide, Docetaxel, Doxorubicin, NOV 002 |
| Enrollment | 41 |
| Start date | Jun 4, 2007 |
| Primary completion | Apr 1, 2011 |
| Completion | Apr 1, 2011 |
| First posted | Jul 11, 2007 |
| Last update posted | Jan 2, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: